Total Funding
52
34
Total FundingPost-IPO Equity raised
Growth Score
-5 pts
Heat Score
2 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
163252
GeNeuro is a clinical stage pharmaceutical company developing a new approach to the treatment of autoimmune diseases.
Hervé Perron: CSO
Miguel Payró: Chief Financial Officer
About the Company
GeNeuro is a biotechnology company that develops therapeutic drugs for diseases associated with the expression of pathogenic proteins of the human endogenous retroviral origin. The company is primarily focused on nervous system diseases such as multiple sclerosis and schizophrenia. Its products include GNbAC1, a therapeutic monoclonal antibody for
the treatment of multiple sclerosis. It also develops diagnostic tests to dose the multiple sclerosis-associated retrovirus-ENV proteins in patients.GeNeuro was founded in 2006 and is based in Plan-Les-Ouates, Switzerland.
